The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics
PR Newswire - Thu Apr 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the GIlead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), MannKind (Nasdaq:MNKD-Free Report), Alkermes (Nasdaq:ALKS-Free Report)andPharmacyclics (Nasdaq
Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
Business Wire - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
M2 - Thu Apr 17, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmclnk/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes' proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes' aripiprazole lauroxil differs from Otsuka/Lundbeck's once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration. Scope - Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aripiprazole Lauroxil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aripiprazole Lauroxil for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 4.1 Diagnosis 4.1.1 Subjective Assessments 4.1.2 Disease Subtypes 4.2 Treatment Overview 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 4.2.2 Maintenance Treatment of Schizophrenia 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Opportunity and Unmet Need 6.1 Unmet Needs Overview 6.1.1 Public Awareness 6.1.2 Early Diagnosis and Treatment 6.1.3 Long-Acting and Advanced Drug Delivery Systems 6.1.4 Effective Management of Negative and Cognitive Symptom Domains 6.2 Gap Analysis 6.2.1 Long-Acting Drug Delivery 6.2.2 Treatment of Negative and Cognitive Symptoms 7 Pipeline Assessment 7.1 Overview 7.2 Early-Stage Pipeline Assessment 7.3 Novel Therapeutic Approaches 7.3.1 Negative Symptoms 7.3.2 Cognitive Symptoms 7.4 Long-Acting Drug Delivery 7.5 Technology Trends Analysis 7.6 Key Drugs in Clinical Development 8 Aripiprazole Lauroxil 8.1 Overview 8.2 Efficacy 8.3 Safety 8.3.1 Dosing and Formulation 8.3.2 Potential Clinical Positioning 8.3.3 Potential Commercial Positioning 8.3.4 Pricing and Reimbursement 8.4 SWOT Analysis 8.5 Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/bm...ipiprazole
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...
Watch for Alkermes to Potentially Rebound After Falling 1.43% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 5:17PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $40.57 to a high of $42.82. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $41.61 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.
Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.
ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.
Gilead Announces Encouraging Sovaldi Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:37PM CDT
Gilead announced encouraging data on Sovaldi as a combination therapy.
Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex
PR Newswire - Thu Apr 10, 11:23AM CDT
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 10, 8:22AM CDT
The price correction in the biotech sector provides an opportunity to invest in stocks that are a combination of strong fundamentals and a favorable Zacks Rank.
Upgrade Alert for Alkermes (ALKS)
Comtex SmarTrend(R) - Thu Apr 10, 7:03AM CDT
Alkermes (NASDAQ:ALKS) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $45.25 on volume of 1.6 million shares, above average daily volume of 1.5 million. Alkermes has overhead space with shares priced $45.25, or 5.3% below the average consensus analyst price target of $47.80. Alkermes shares should encounter resistance at the 50-day moving average (MA) of $47.65 and support at its 200-day MA of $38.84.
'Mad Money' Lightning Round: Buy, Buy, Buy Baxter
at The Street - Thu Apr 10, 5:00AM CDT
Cramer is disappointed by Boardwalk Partners, dislikes Prospect Capital but loves Kinder Morgan Energy Partners and Alkermes
Jim Cramer's 'Mad Money' Recap: Recipe for a Rally
at The Street - Wed Apr 09, 7:15PM CDT
To understand Wednesday's rally you need to know what prompted the earlier selloff, Cramer says.
Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 5:30PM CDT
Oncolytics Biotech reported additional encouraging data from the REO 018 study on Reolysin.
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.